SPPI - Spectrum Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.70
-0.46 (-5.64%)
At close: 4:00PM EDT

7.70 0.00 (0.00%)
After hours: 4:51PM EDT

Stock chart is not supported by your current browser
Previous Close8.16
Open8.09
Bid7.71 x 800
Ask8.39 x 3200
Day's Range7.70 - 8.14
52 Week Range6.22 - 25.29
Volume450,784
Avg. Volume903,064
Market Cap848.24M
Beta (3Y Monthly)3.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-12-18
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire7 days ago

    Spectrum Pharmaceuticals to Present Corporate Update at the 20th Annual B. Riley FBR Investor Conference on May 23rd

    Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the 20th Annual B. Riley FBR Investor Conference being held in Beverly Hills, CA. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology.

  • Business Wire13 days ago

    Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results and Pipeline Update

    HENDERSON, Nev.-- -- Topline results in the previously treated EGFR cohort of the poziotinib ZENITH20 trial are expected in Q4 2019. Integrated data from the two Phase 3 ROLONTIS ® clinical trials will be presented in a poster session at the American Society of Clinical Oncology 2019 annual meeting. Spectrum is working on filing the ROLONTIS Biologics License Application as soon as possible. Spectrum ...

  • Business Wire14 days ago

    Spectrum Announces Asset Purchase and License for a Novel Immuno-Oncology Platform including Two Early Stage Assets

    Spectrum Pharmaceuticals, Inc. (SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the closure of an asset purchase and license agreement with ImmunGene, Inc., a privately held biotechnology company. The deal includes an exclusive license for the intellectual property related to the FIT antibody-interferon fusion technology drug delivery platform originally developed by scientists at UCLA. Research for this program received financial support through the Therapy Acceleration Program® of The Leukemia & Lymphoma Society, Inc. (LLS), and an LLS research grant to UCLA.

  • Business Wire21 days ago

    Spectrum Pharmaceuticals Announces First Quarter 2019 Financial Results Conference Call

    Spectrum Pharmaceuticals , announced today it will host a conference call with management to discuss the first quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, May 9, 2019 at 4:30 p.m.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 9

    Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today that an overview of the company's business strategy and development-stage programs will be given at the H.C. Wainwright Global Life Sciences Conference being held in London. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind ON Semiconductor, Pilgrim's Pride, Merck & Co., Healthcare Services Group, Genomic Health, and Spectrum Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Provides BLA Filing Update for ROLONTIS® (eflapegrastim)

    Spectrum Pharmaceuticals, Inc. (SPPI) announced today that due to the U.S. Food and Drug Administration’s (FDA) request for additional manufacturing-related information for ROLONTIS, the company has voluntarily withdrawn its Biologics License Application (BLA). Spectrum plans to resubmit a revised BLA as soon as possible. The FDA did not cite concerns related to the pre-clinical and clinical modules of the BLA or the need for additional clinical studies.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals to Present Corporate Update at the Oppenheimer 29th Annual Healthcare Conference on March 20

    Spectrum Pharmaceuticals (SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the Oppenheimer 29th Annual Healthcare Conference being held in New York. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology.

  • Business Wire3 months ago

    Spectrum Pharmaceuticals Announces the Completion of the Sale of its Marketed Portfolio

    Spectrum Pharmaceuticals, Inc. (SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today completed the sale of its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C., a step-down subsidiary of Aurobindo Pharma Limited, India. “The completion of this sale marks a significant pivot point in Spectrum’s history as we focus our efforts on our two promising late stage assets, ROLONTIS® and poziotinib,” stated Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. In addition, the company is eligible to receive up to $140 million in milestone payments.

  • Business Wire3 months ago

    Spectrum Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results and Pipeline Update

    HENDERSON, Nev.-- -- Poziotinib enrollment completed in previously treated EGFR cohort of ZENITH20 trial; topline results are expected in Q4 2019 ROLONTIS ® Biologics License Application was submitted to the FDA Q4 Revenues were $29.4 million, including $28.0 million in product sales; full year revenues were $109.3 million including $104.5 million in product sales Spectrum Pharmaceuticals, Inc. , a ...

  • Business Wire3 months ago

    Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results Conference Call

    Spectrum Pharmaceuticals (SPPI), announced today it will host a conference call with management to discuss the fourth quarter and full year 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, February 28, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

  • Business Wire3 months ago

    Spectrum Pharmaceuticals to Present Corporate Update at the Guggenheim Healthcare Talks Idea Forum on February 14

    Spectrum Pharmaceuticals (SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum | Oncology Day being held in New York. The company presentation is on Thursday, February 14, 2019, at 9:30 AM ET. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com.

  • Business Wire4 months ago

    Spectrum Pharmaceuticals Sells Marketed Portfolio to Acrotech Biopharma L.L.C. to Focus on New and Innovative Therapies for Cancer Patients

    HENDERSON, Nev.-- -- Spectrum will receive $160 million in an upfront cash payment and up to $140 million in regulatory and sales-based milestones Staff size will be reduced by approximately 40 percent with the majority of impacted staff transitioning to Acrotech Spectrum will retain a core group of commercial talent to lead the launch of ROLONTIS ®   and poziotinib Management to host a webcast on ...

  • Business Wire5 months ago

    Spectrum Pharmaceuticals Announces Full Enrollment of the Poziotinib EGFR Cohort for Previously Treated Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced full enrollment of cohort 1 (N=87) for previously treated Non-Small Cell Lung Cancer (NSCLC) patients with EGFR exon 20 insertion mutations with sites across the U.S., Europe, and Canada. The EGFR previously treated cohort is part of the ZENITH20 trial – an open-label, multi-center, global Phase 2 trial evaluating NSCLC patients with EGFR or HER2 exon 20 insertion mutations. “The rapid rate at which we enrolled our Phase 2 previously treated EGFR exon 20 insertion mutations cohort speaks to the critical unmet medical need and demonstrates that the poziotinib program is aggressively advancing,” said Joe Turgeon, President and Chief Executive Officer of Spectrum Pharmaceuticals.

  • Business Wire5 months ago

    Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS® (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that the company submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ROLONTIS® (eflapegrastim). “ROLONTIS is an important and significant future growth driver for our company,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. The BLA for ROLONTIS is supported by data from two identically designed Phase 3 clinical trials, ADVANCE and RECOVER, which evaluated the safety and efficacy of ROLONTIS in 643 early-stage breast cancer patients for the treatment of neutropenia due to myelosuppressive cytoxic chemotherapy.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and MannKind

    NEW YORK, NY / ACCESSWIRE / December 20, 2018 / U.S. equities closed down on Wednesday as the anticipated interest rate increase was confirmed by the Federal Reserve, following Chairman Jerome Powell’s ...

  • Business Wire5 months ago

    Spectrum Pharmaceuticals Provides Poziotinib Update

    Spectrum Pharmaceuticals, Inc. (SPPI), today announced that based on a subset of data from MD Anderson’s ongoing Phase 2 study, the U.S. Food and Drug Administration (FDA) did not grant Breakthrough Therapy Designation (BTD) to poziotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 mutations. Breakthrough Therapy Designation is one of several FDA programs designed to expedite the review of drugs to treat serious or life threatening conditions. Spectrum’s BTD application included data from 30 patients from the MD Anderson Phase 2 study who had failed platinum-based chemotherapy.

  • Business Wire6 months ago

    Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS® (eflapegrastim) at the 2018 SABCS Annual Meeting

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that data from the Phase 3 RECOVER clinical study was presented during the 2018 San Antonio Breast Cancer Symposium® (SABCS). ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing treatment with myelosuppressive cytotoxic chemotherapy.

  • GlobeNewswire6 months ago

    Report: Exploring Fundamental Drivers Behind CVS Health, TransCanada, Nektar Therapeutics, LendingTree, Spectrum Pharmaceuticals, and TripAdvisor — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire6 months ago

    Spectrum Pharmaceuticals Announces Positive Results from Phase 2 Trial Evaluating Use of Oral Leucovorin to Potentially Mitigate Mucositis in Patients Treated with FOLOTYN® (pralatrexate)

    HENDERSON, Nev.-- -- In practice, FOLOTYN use has caused Grade 2 or higher oral mucositis in more than half of patients, potentially impacting treatment of relapsed or refractory Peripheral T-cell Lymphoma This was the first prospective study to evaluate the effect of oral leucovorin in preventing or reducing FOLOTYN-related oral mucositis in patients with hematological malignancies, including PTCL ...

  • Business Wire6 months ago

    Spectrum Pharmaceuticals Highlights Three Posters at the 60th Annual Meeting of the American Society of Hematology

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced presentations of clinical and scientific data related to Peripheral T-cell Lymphoma (PTCL) and EVOMELA® (melphalan) at the 60th Annual Meeting of the American Society of Hematology (ASH) being held in San Diego, California, from December 1-4, 2018. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies.

  • Business Wire6 months ago

    Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca to its Board of Directors

    Spectrum Pharmaceuticals Inc., (SPPI) a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, today announced the appointment of Jeffrey Vacirca, MD, FACP to its Board of Directors. Dr. Vacirca is a practicing oncologist and the current president of the Community Oncology Alliance, an advocacy group focused on supporting community oncology clinics. Additionally, Dr. Vacirca is the medical director of the nation’s largest community oncology group purchasing organization, International Oncology Network and the CEO and managing partner at North Shore Hematology Oncology Associates.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Trending Tickers: Omeros and Spectrum Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual ...

  • Business Wire6 months ago

    Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update and Financial Results

    HENDERSON, Nev.-- -- Poziotinib interim data from the MD Anderson Phase 2 study presented in Q3 demonstrated strong efficacy in metastatic, heavily pretreated EGFR and HER2 exon 20 mutations in NSCLC patients Spectrum has submitted a request for Breakthrough Therapy Designation for poziotinib and expects a response from the FDA by end of the year Enrollment of the EGFR, previously treated cohort in ...

  • Business Wire6 months ago

    Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 London Healthcare Conference on November 14

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at the Jefferies 2018 London Healthcare Conference being held in London. A live webcast of Spectrum's presentation will be available at www.sppirx.com. Spectrum Pharmaceuticals is a leading biopharmaceutical company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.